A Phase 1 interventional study of Placebo matched to M2951 and Moxifloxacin in Healthy, sponsored by Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany. Completed at 1 site in Germany. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-11-13.
Sponsored by Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany (part of Merck KGaA, Darmstadt, Germany) · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to assess potential effects of M2951 on cardiac repolarization (i.e. prolongation of QT interval).
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany is the lead sponsor of 56 studies on the registry; 5 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive one of the four interventions in a sequence decided at randomization.
Drug: Placebo matched to M2951 · Drug: Moxifloxacin · Drug: M2951 Low Dose · Drug: M2951 High Dose
Participants will receive one of the four interventions in a sequence decided at randomization.
Drug: Placebo matched to M2951 · Drug: Moxifloxacin · Drug: M2951 Low Dose · Drug: M2951 High Dose
Participants will receive one of the four interventions in a sequence decided at randomization.
Drug: Placebo matched to M2951 · Drug: Moxifloxacin · Drug: M2951 Low Dose · Drug: M2951 High Dose
Participants will receive one of the four interventions in a sequence decided at randomization.
Drug: Placebo matched to M2951 · Drug: Moxifloxacin · Drug: M2951 Low Dose · Drug: M2951 High Dose
Participants will receive single oral dose of placebo matched to M2951 in either of study periods (period 1 or period 2 or period 3 or period 4) under fasted conditions.
Participants will receive single oral dose of moxifloxacin in either of study periods (period 1 or period 2 or period 3 or period 4) under fasted conditions.
Participants will receive single oral low dose of M2951 in either of study periods (period 1 or period 2 or period 3 or period 4) under fasted conditions.
Also known as: Evobrutinib, MSC2364447C
Participants will receive single oral high dose of M2951 in either of study periods (period 1 or period 2 or period 3 or period 4) under fasted conditions.
Also known as: Evobrutinib, MSC2364447C
Placebo-corrected Change From Baseline in Corrected QT Interval by Fridericia' Formula (QTcF) for Evobrutinib
A linear mixed-effects model was used to analyze the relationship between evobrutinib and MSC2729909A concentrations and ΔQTc. Based on this model, drug-induced ΔΔQTc and its two-sided 90% CI was predicted over the clinical concentration range and at concentrations corresponding to the observed geometric mean Cmax following administration of 45 mg and 225 mg evobrutinib. The higher geometric mean Cmax calculated based on the PK and ECG Analysis Sets was considered.
Time frame: Baseline and from 1 hour before any administration until 24 hours post-administration at the following timepoints: -1-hour, 5 min, 10 min, 20 min, 0.5, 1, 1.5, 2, 3, 4, 8 and 24 hours
Placebo-corrected Change From Baseline in Corrected QT Interval by Fridericia' Formula (QTcF) for Moxifloxacin
A linear mixed-effects model was used to analyze the relationship between moxifloxacin concentrations and ΔQTc. Based on this model, drug-induced ΔΔQTc and its two-sided 90% CI was predicted. The higher geometric mean Cmax calculated based on the PK and ECG Analysis Sets was considered.
Time frame: From 1 hour before any administration until 24 hours post-administration at the following timepoints: -1-hour, 5 min, 10 min, 20 min, 0.5, 1, 1.5, 2, 3, 4, 8 and 24 hours
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product, regardless of causal relationship with this treatment.Therefore, an AE can be any unfavorable and unintended sign (including an abnormallaboratory finding), symptom, or disease temporally associated with the use of amedicinal product, regardless if it is considered related to the medicinal product.Serious AE: AE that resulted in any of the following outcomes: death; life threatening;persistent/significant disability/incapacity; initial/prolonged inpatient hospitalization;congenital anomaly/birth defect. TEAEs are defined as AEs that were reported orworsened on or after start of study drug dosing through the Safety Follow-up Visit.TEAEs included both serious TEAEs and non-serious TEAEs. Treatment related AEs:reasonably related to the study drug/study treatment.
Time frame: Up to 3 months
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) Based on Severity
Severity of adverse events (AE) were assessed by the investigator. The Investigator assessed the intensity of each AE and SAE reported during the study and assigned it to 1 of the following categories: 1\. Mild: A type of adverse event that is usually transient and may require only minimal treatment or therapeutic intervention. The event does not generally interfere with usual activities of daily living. 2. Moderate: A type of adverse event that is usually alleviated with additional specific therapeutic intervention. The event interferes with usual activities of daily living, causing discomfort but poses no significant or permanent risk of harm to the research participant. 3. Severe: A type of adverse event that interrupts usual activities of daily living, or significantly affects clinical status, or may require intensive therapeutic intervention. Number of participants with severe adverse events were reported.
Time frame: Up to 3 months
Number of Participants With Clinically Significant Abnormalities From Baseline in Safety Laboratory Tests
The laboratory measurements included hematology, blood chemistry and urinalysis. Number of participants with clinically significant abnormalities from baseline were reported. Clinically Significance was decided by investigator.
Time frame: Up to Day 29
Number of Participants With Clinically Significant Abnormalities From Baseline in Vital Signs
Vital sign assessment included blood pressure, pulse rate, body temperature and respiration (frequency per minute). Number of participants with clinically significant abnormalities in vital signs were reported. Clinically significance was decided by investigator.
Time frame: Up to Day 29
Number of Participants With Clinically Significant Changes From Baseline in Electroencephalogram (EEG) and Electrocardiogram (ECG) Findings
The 12-lead ECG recordings were obtained after 5 minutes of rest in a semi-supine position. ECG recordings included rhythm, ventricular rate, PR interval, QRS duration, QT and QTc intervals. Number of participants with clinically significant abnormalities were reported. Clinically significance was decided by investigator.
Time frame: Up to Day 29
Area Under the Blood-Concentration Time Curve From Time Zero to 24 Hours Post-Dose (AUC 0-24) of Evobrutinib
AUC from time zero to 24 hours post dose, calculated using the mixed log linear trapezoidal rule (linear up, log down) using the nominal dosing interval.
Time frame: Pre-dose up to 24 hours post-dose on Days 1, 8, 15, and 22
Area Under the Plasma-Concentration Time Curve From Time Zero Extrapolated to Infinity (AUC 0-inf) of Evobrutinib
The AUC from time zero (= dosing time) extrapolated to infinity, based on the predicted value for the concentration at t last, as estimated using the linear regression from lambda (λ)z determination.
Time frame: Pre-dose up to 24 hours post-dose on Days 1, 8, 15, and 22
Maximum Observed Plasma Concentration (Cmax) of Evobrutinib
Cmax is the maximum observed plasma concentration. Cmax was obtained directly from the concentration versus time curve.
Time frame: Pre-dose up to 24 hours post-dose on Days 1, 8, 15, and 22
Time to Reach Maximum Blood Concentration (Tmax) of Evobrutinib
Time to reach the maximum blood concentration (Tmax) was obtained directly from the concentration versus time curve.
Time frame: Pre-dose up to 24 hours post-dose on Days 1, 8, 15, and 22
Apparent Terminal Half-life (t1/2) of Evobrutinib
Terminal half-life is the time measured for the concentration to decrease by one half. Terminal half-life calculated by natural log 2 divided by lambda z.
Time frame: Pre-dose up to 24 hours post-dose on Days 1, 8, 15, and 22
Area Under the Blood-Concentration Time Curve From Time Zero to 24 Hours Post-Dose (AUC 0-24) Of Moxifloxacin
AUC from time zero to 24 hours post dose, calculated using the mixed log linear trapezoidal rule (linear up, log down) using the nominal dosing interval.
Time frame: Pre-dose up to 24 hours post-dose on Days 1, 8, 15, and 22
Maximum Observed Plasma Concentration (Cmax) of Moxifloxacin
Cmax is the maximum observed plasma concentration. Cmax was obtained directly from the concentration versus time curve.
Time frame: Pre-dose up to 24 hours post-dose on Days 1, 8, 15, and 22
Area Under the Plasma-Concentration Time Curve From Time Zero Extrapolated to Infinity (AUC 0-inf) of Moxifloxacin
The AUC from time zero (= dosing time) extrapolated to infinity, based on the predicted value for the concentration at t last, as estimated using the linear regression from lambda (λ)z determination.
Time frame: Pre-dose up to 24 hours post-dose on Days 1, 8, 15, and 22
Time to Reach Maximum Blood Concentration (Tmax) of Moxifloxacin
Time to reach the maximum blood concentration (Tmax) was obtained directly from the concentration versus time curve.
Time frame: Pre-dose up to 24 hours post-dose on Days 1, 8, 15, and 22
Effect of Evobrutinib on ECG Parameters: ECG Mean Heart Rate
The effect of evobrutinib on baseline-corrected measurements of Heart rate was summarized by treatment and time points using descriptive statistics. Absolute change from baseline values was reported.
Time frame: Baseline, and post-dose at 15 minutes, 30 minutes, 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours, 16 hours, and 24 hours
Effect of Evobrutinib on ECG Parameters: RR Interval
The effect of evobrutinib on baseline-corrected measurements of RR interval was summarized by treatment and time points using descriptive statistics. Absolute change from baseline values was reported.
Time frame: Baseline, and post-dose at 15 minutes, 30 minutes, 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours, 16 hours, and 24 hours
Effect of Evobrutinib on ECG Parameters: QT Interval
The effect of evobrutinib on baseline-corrected measurements of QT interval was summarized by treatment and time points using descriptive statistics. Absolute change from baseline values was reported.
Time frame: Baseline, and post-dose at 15 minutes, 30 minutes, 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours, 16 hours, and 24 hours
Effect of Evobrutinib on ECG Parameters: QTcF Interval
The effect of evobrutinib on baseline-corrected measurements of QTcF was summarized by treatment and time points using descriptive statistics. Absolute change from baseline values was reported.
Time frame: Baseline, and post-dose at 15 minutes, 30 minutes, 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours, 16 hours, and 24 hours
Effect of Evobrutinib on ECG Parameters: QTcP Interval
The effect of evobrutinib on baseline-corrected measurements of QTcP was summarized by treatment and time points using descriptive statistics. Absolute change from baseline values was reported.
Time frame: Baseline, and post-dose at 15 minutes, 30 minutes, 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours, 16 hours, and 24 hours
Effect of Evobrutinib on ECG Parameters: PR Interval
The effect of evobrutinib on baseline-corrected measurements of PR interval was summarized by treatment and time points using descriptive statistics. Absolute change from baseline values was reported.
Time frame: Baseline, and post-dose at 15 minutes, 30 minutes, 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours, 16 hours, and 24 hours
Effect of Evobrutinib on ECG Parameters: QRS Duration
The effect of evobrutinib on baseline-corrected measurements of QRS duration was summarized by treatment and time points using descriptive statistics. Absolute change from baseline values was reported.
Time frame: Baseline, and post-dose at 15 minutes, 30 minutes, 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours, 16 hours, and 24 hours
| Milestone | Sequence 1 | Sequence 2 | Sequence 3 | Sequence 4 |
|---|---|---|---|---|
| Started | 9 | 9 | 9 | 9 |
| Completed | 7 | 7 | 8 | 8 |
| Not completed | 2 | 2 | 1 | 1 |
| Withdrew: Adverse event | 1 | 1 | 1 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 | 0 |
| Withdrew: Participant did not meet all eligibility criteria, admission drug screen positive | 1 | 0 | 0 | 0 |
| Withdrew: Participant discontinued prior to first dosing | 0 | 0 | 0 | 1 |
A linear mixed-effects model was used to analyze the relationship between evobrutinib and MSC2729909A concentrations and ΔQTc. Based on this model, drug-induced ΔΔQTc and its two-sided 90% CI was predicted over the clinical concentration range and at concentrations corresponding to the observed geometric mean Cmax following administration of 45 mg and 225 mg evobrutinib. The higher geometric mean Cmax calculated based on the PK and ECG Analysis Sets was considered.
| milliseconds | Evobrutinib 45mg | Evobrutinib 225mg |
|---|---|---|
| Placebo-corrected Change From Baseline in Corrected QT Interval by Fridericia' Formula (QTcF) for Evobrutinib | -1.62 (-2.15 to -1.09) | -2.28 (-3.63 to -0.93) |
A linear mixed-effects model was used to analyze the relationship between moxifloxacin concentrations and ΔQTc. Based on this model, drug-induced ΔΔQTc and its two-sided 90% CI was predicted. The higher geometric mean Cmax calculated based on the PK and ECG Analysis Sets was considered.
| milliseconds | Moxifloxacin 400mg |
|---|---|
| Placebo-corrected Change From Baseline in Corrected QT Interval by Fridericia' Formula (QTcF) for Moxifloxacin | 12.2 (10.3 to 14.1) |
An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product, regardless of causal relationship with this treatment.Therefore, an AE can be any unfavorable and unintended sign (including an abnormallaboratory finding), symptom, or disease temporally associated with the use of amedicinal product, regardless if it is considered related to the medicinal product.Serious AE: AE that resulted in any of the following outcomes: death; life threatening;persistent/significant disability/incapacity; initial/prolonged inpatient hospitalization;congenital anomaly/birth defect. TEAEs are defined as AEs that were reported orworsened on or after start of study drug dosing through the Safety Follow-up Visit.TEAEs included both serious TEAEs and non-serious TEAEs. Treatment related AEs:reasonably related to the study drug/study treatment.
| Participants | Evobrutinib 45mg | Evobrutinib 225mg | Moxifloxacin 400mg | Placebo |
|---|---|---|---|---|
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | 8 | 5 | 5 | 8 |
Severity of adverse events (AE) were assessed by the investigator. The Investigator assessed the intensity of each AE and SAE reported during the study and assigned it to 1 of the following categories: 1\. Mild: A type of adverse event that is usually transient and may require only minimal treatment or therapeutic intervention. The event does not generally interfere with usual activities of daily living. 2. Moderate: A type of adverse event that is usually alleviated with additional specific therapeutic intervention. The event interferes with usual activities of daily living, causing discomfort but poses no significant or permanent risk of harm to the research participant. 3. Severe: A type of adverse event that interrupts usual activities of daily living, or significantly affects clinical status, or may require intensive therapeutic intervention. Number of participants with severe adverse events were reported.
| Participants | Evobrutinib 45mg | Evobrutinib 225mg | Moxifloxacin 400mg | Placebo |
|---|---|---|---|---|
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) Based on Severity | 0 | 0 | 0 | 0 |
The laboratory measurements included hematology, blood chemistry and urinalysis. Number of participants with clinically significant abnormalities from baseline were reported. Clinically Significance was decided by investigator.
| Participants | Evobrutinib 45mg | Evobrutinib 225mg | Moxifloxacin 400mg | Placebo |
|---|---|---|---|---|
| Number of Participants With Clinically Significant Abnormalities From Baseline in Safety Laboratory Tests | 0 | 0 | 0 | 0 |
Vital sign assessment included blood pressure, pulse rate, body temperature and respiration (frequency per minute). Number of participants with clinically significant abnormalities in vital signs were reported. Clinically significance was decided by investigator.
| Participants | Evobrutinib 45mg | Evobrutinib 225mg | Moxifloxacin 400mg | Placebo |
|---|---|---|---|---|
| Number of Participants With Clinically Significant Abnormalities From Baseline in Vital Signs | 0 | 0 | 0 | 0 |
The 12-lead ECG recordings were obtained after 5 minutes of rest in a semi-supine position. ECG recordings included rhythm, ventricular rate, PR interval, QRS duration, QT and QTc intervals. Number of participants with clinically significant abnormalities were reported. Clinically significance was decided by investigator.
| Participants | Evobrutinib 45mg | Evobrutinib 225mg | Moxifloxacin 400mg | Placebo |
|---|---|---|---|---|
| Number of Participants With Clinically Significant Changes From Baseline in Electroencephalogram (EEG) and Electrocardiogram (ECG) Findings | 0 | 0 | 0 | 0 |
AUC from time zero to 24 hours post dose, calculated using the mixed log linear trapezoidal rule (linear up, log down) using the nominal dosing interval.
| hour*nanogram/milliliter | Evobrutinib 45mg | Evobrutinib 225mg |
|---|---|---|
| Area Under the Blood-Concentration Time Curve From Time Zero to 24 Hours Post-Dose (AUC 0-24) of Evobrutinib | 249 ± 38.4 | 1420 ± 37.5 |
The AUC from time zero (= dosing time) extrapolated to infinity, based on the predicted value for the concentration at t last, as estimated using the linear regression from lambda (λ)z determination.
| h*ng/mL | Evobrutinib 45mg | Evobrutinib 225mg |
|---|---|---|
| Area Under the Plasma-Concentration Time Curve From Time Zero Extrapolated to Infinity (AUC 0-inf) of Evobrutinib | 248 ± 38.4 | 1420 ± 37.5 |
Cmax is the maximum observed plasma concentration. Cmax was obtained directly from the concentration versus time curve.
| ng/mL | Evobrutinib 45mg | Evobrutinib 225mg |
|---|---|---|
| Maximum Observed Plasma Concentration (Cmax) of Evobrutinib | 123 ± 45.8 | 670 ± 51.3 |
Time to reach the maximum blood concentration (Tmax) was obtained directly from the concentration versus time curve.
| hours | Evobrutinib 45mg | Evobrutinib 225mg |
|---|---|---|
| Time to Reach Maximum Blood Concentration (Tmax) of Evobrutinib | 0.500 (0.267 to 2.02) | 0.500 (0.250 to 2.03) |
Terminal half-life is the time measured for the concentration to decrease by one half. Terminal half-life calculated by natural log 2 divided by lambda z.
| hours | Evobrutinib 45mg | Evobrutinib 225mg |
|---|---|---|
| Apparent Terminal Half-life (t1/2) of Evobrutinib | 1.32 ± 22.7 | 2.09 ± 33.8 |
AUC from time zero to 24 hours post dose, calculated using the mixed log linear trapezoidal rule (linear up, log down) using the nominal dosing interval.
| h*ng/mL | Moxifloxacin 400mg |
|---|---|
| Area Under the Blood-Concentration Time Curve From Time Zero to 24 Hours Post-Dose (AUC 0-24) Of Moxifloxacin | 19600 ± 19.6 |
Cmax is the maximum observed plasma concentration. Cmax was obtained directly from the concentration versus time curve.
| ng/mL | Moxifloxacin 400mg |
|---|---|
| Maximum Observed Plasma Concentration (Cmax) of Moxifloxacin | 2000 ± 30.3 |
The AUC from time zero (= dosing time) extrapolated to infinity, based on the predicted value for the concentration at t last, as estimated using the linear regression from lambda (λ)z determination.
| h*ng/mL | Moxifloxacin 400mg |
|---|---|
| Area Under the Plasma-Concentration Time Curve From Time Zero Extrapolated to Infinity (AUC 0-inf) of Moxifloxacin | 24900 ± 19.8 |
Time to reach the maximum blood concentration (Tmax) was obtained directly from the concentration versus time curve.
| hours | Moxifloxacin 400mg |
|---|---|
| Time to Reach Maximum Blood Concentration (Tmax) of Moxifloxacin | 1.50 (0.250 to 4.00) |
The effect of evobrutinib on baseline-corrected measurements of Heart rate was summarized by treatment and time points using descriptive statistics. Absolute change from baseline values was reported.
| beats/min | Evobrutinib 45mg | Evobrutinib 225mg | Moxifloxacin 400mg | Placebo |
|---|---|---|---|---|
| Baseline | 58.1 ± 8.38 | 58.6 ± 7.38 | 58.7 ± 7.90 | 57.9 ± 7.61 |
| 15 Minutes Post-dose | 0.6 ± 3.26 | 1.3 ± 3.83 | 0.0 ± 2.58 | 0.8 ± 2.65 |
| 30 Minutes Post-dose | 0.0 ± 3.43 | 0.2 ± 3.26 | 1.6 ± 3.57 | 0.7 ± 2.98 |
| 1 Hour Post-dose | 1.7 ± 3.68 | 1.0 ± 4.00 | 2.6 ± 3.80 | 3.2 ± 4.10 |
| 1.5 Hour Post-dose | 1.7 ± 3.26 | 1.1 ± 3.60 | 3.0 ± 3.48 | 3.9 ± 4.03 |
| 2 Hour Post-dose | 0.6 ± 3.10 | 1.4 ± 2.21 | 3.6 ± 4.76 | 2.8 ± 3.05 |
| 2.5 Hour Post-dose | 0.4 ± 4.04 | 0.7 ± 3.73 | 1.9 ± 4.22 | 1.2 ± 3.64 |
| 3 Hour Post-dose | -0.4 ± 4.43 | -0.0 ± 3.28 | 2.4 ± 3.63 | 1.9 ± 4.13 |
| 4 Hour Post-dose | 0.8 ± 3.67 | 0.8 ± 3.54 | 2.7 ± 6.52 | 2.7 ± 4.03 |
| 6 Hour Post-dose | 6.6 ± 6.42 | 6.1 ± 4.85 | 7.8 ± 4.84 | 9.3 ± 5.53 |
| 8 Hour Post-dose | 4.2 ± 5.85 | 2.3 ± 5.29 | 5.5 ± 4.24 | 5.2 ± 5.30 |
| 12 Hour Post-dose | 1.3 ± 5.36 | -0.1 ± 4.63 | 2.6 ± 5.62 | 0.7 ± 4.75 |
| 16 Hour Post-dose | 3.5 ± 5.91 | 2.1 ± 5.73 | 4.6 ± 5.25 | 5.6 ± 5.16 |
| 24 Hour Post-dose | 6.0 ± 7.88 | 2.6 ± 5.62 | 4.3 ± 5.38 | 5.3 ± 5.69 |
The effect of evobrutinib on baseline-corrected measurements of RR interval was summarized by treatment and time points using descriptive statistics. Absolute change from baseline values was reported.
| milliseconds | Evobrutinib 45mg | Evobrutinib 225mg | Moxifloxacin 400mg | Placebo |
|---|---|---|---|---|
| Baseline | 1057.4 ± 146.41 | 1044.0 ± 139.39 | 1043.4 ± 144.03 | 1056.1 ± 140.61 |
| 15 Minutes Post-dose | -14.8 ± 60.09 | -24.4 ± 63.48 | 0.6 ± 45.64 | -13.8 ± 54.73 |
| 30 Minutes Post-dose | -4.2 ± 65.10 | -4.9 ± 55.65 | -26.6 ± 66.04 | -11.3 ± 48.52 |
| 1 Hour Post-dose | -30.2 ± 72.81 | -17.0 ± 60.28 | -40.3 ± 62.87 | -47.3 ± 58.95 |
| 1.5 Hour Post-dose | -34.4 ± 65.46 | -17.2 ± 59.43 | -52.5 ± 59.00 | -66.0 ± 78.10 |
| 2 Hour Post-dose | -14.0 ± 57.06 | -26.2 ± 40.34 | -65.0 ± 81.34 | -49.9 ± 57.51 |
| 2.5 Hour Post-dose | -10.8 ± 69.18 | -10.6 ± 70.27 | -37.4 ± 79.84 | -18.8 ± 65.83 |
| 3 Hour Post-dose | 0.2 ± 80.54 | -1.8 ± 65.55 | -45.2 ± 74.46 | -31.8 ± 81.31 |
| 4 Hour Post-dose | -20.1 ± 67.37 | -15.9 ± 61.57 | -48.1 ± 99.08 | -44.6 ± 71.37 |
| 6 Hour Post-dose | -112.1 ± 115.18 | -101.1 ± 94.08 | -127.3 ± 89.62 | -146.5 ± 94.86 |
| 8 Hour Post-dose | -74.0 ± 95.45 | -38.8 ± 95.45 | -97.8 ± 83.82 | -83.7 ± 88.55 |
| 12 Hour Post-dose | -24.8 ± 94.78 | 1.4 ± 89.18 | -47.3 ± 103.93 | -15.7 ± 93.15 |
| 16 Hour Post-dose | -61.3 ± 98.99 | -39.9 ± 105.20 | -83.3 ± 99.08 | -94.7 ± 84.41 |
| 24 Hour Post-dose | -98.8 ± 127.77 | -42.6 ± 106.76 | -74.0 ± 101.40 | -85.1 ± 88.69 |
The effect of evobrutinib on baseline-corrected measurements of QT interval was summarized by treatment and time points using descriptive statistics. Absolute change from baseline values was reported.
| milliseconds | Evobrutinib 45mg | Evobrutinib 225mg | Moxifloxacin 400mg | Placebo |
|---|---|---|---|---|
| Baseline | 395.8 ± 28.44 | 393.2 ± 27.84 | 394.5 ± 26.29 | 396.4 ± 27.77 |
| 15 Minutes Post-dose | -0.1 ± 6.99 | -1.5 ± 6.70 | 0.1 ± 6.34 | 1.2 ± 8.39 |
| 30 Minutes Post-dose | 0.6 ± 8.71 | -0.5 ± 5.61 | -1.7 ± 7.29 | 0.1 ± 7.44 |
| 1 Hour Post-dose | -5.2 ± 8.86 | -2.8 ± 7.99 | 3.6 ± 10.74 | -5.0 ± 9.08 |
| 1.5 Hour Post-dose | -8.0 ± 8.12 | -6.0 ± 8.93 | 3.2 ± 10.41 | -8.2 ± 11.75 |
| 2 Hour Post-dose | -4.3 ± 7.63 | -6.9 ± 6.62 | 3.5 ± 13.02 | -7.4 ± 10.21 |
| 2.5 Hour Post-dose | -4.5 ± 9.55 | -5.4 ± 9.46 | 5.5 ± 11.71 | -4.1 ± 10.14 |
| 3 Hour Post-dose | -3.5 ± 10.58 | -3.6 ± 9.31 | 5.3 ± 12.19 | -6.0 ± 12.45 |
| 4 Hour Post-dose | -5.7 ± 9.95 | -4.4 ± 10.67 | 2.4 ± 16.10 | -7.8 ± 10.66 |
| 6 Hour Post-dose | -19.2 ± 15.98 | -16.9 ± 13.10 | -13.6 ± 13.12 | -22.3 ± 14.43 |
| 8 Hour Post-dose | -13.7 ± 13.06 | -11.3 ± 13.33 | -8.2 ± 12.25 | -14.2 ± 12.80 |
| 12 Hour Post-dose | -2.7 ± 14.12 | -0.7 ± 13.23 | 1.4 ± 14.28 | -1.7 ± 12.04 |
| 16 Hour Post-dose | -4.1 ± 14.04 | -0.8 ± 15.15 | -0.9 ± 13.19 | -8.5 ± 13.26 |
| 24 Hour Post-dose | -16.3 ± 18.95 | -9.5 ± 13.66 | -8.5 ± 13.92 | -15.8 ± 12.30 |
The effect of evobrutinib on baseline-corrected measurements of QTcF was summarized by treatment and time points using descriptive statistics. Absolute change from baseline values was reported.
| milliseconds | Evobrutinib 45mg | Evobrutinib 225mg | Moxifloxacin 400mg | Placebo |
|---|---|---|---|---|
| Baseline | 389.4 ± 18.08 | 388.4 ± 17.88 | 389.8 ± 17.28 | 390.0 ± 17.58 |
| 15 Minutes Post-dose | 1.6 ± 4.50 | 1.6 ± 4.66 | -0.1 ± 3.91 | 2.8 ± 3.75 |
| 30 Minutes Post-dose | 0.8 ± 5.08 | 0.0 ± 3.77 | 1.8 ± 5.90 | 1.6 ± 4.26 |
| 1 Hour Post-dose | -1.2 ± 4.49 | -0.7 ± 4.62 | 8.8 ± 7.14 | 1.3 ± 5.16 |
| 1.5 Hour Post-dose | -3.7 ± 4.50 | -3.8 ± 5.04 | 9.8 ± 8.09 | 0.2 ± 5.46 |
| 2 Hour Post-dose | -2.7 ± 3.77 | -3.6 ± 3.98 | 11.7 ± 7.92 | -1.1 ± 5.61 |
| 2.5 Hour Post-dose | -3.3 ± 5.26 | -3.9 ± 4.87 | 10.0 ± 6.33 | -1.7 ± 4.52 |
| 3 Hour Post-dose | -3.7 ± 5.89 | -3.4 ± 4.64 | 10.8 ± 5.78 | -1.9 ± 5.29 |
| 4 Hour Post-dose | -3.3 ± 5.34 | -2.4 ± 5.80 | 8.4 ± 7.03 | -2.0 ± 5.54 |
| 6 Hour Post-dose | -5.0 ± 7.51 | -4.0 ± 7.07 | 3.0 ± 8.24 | -3.4 ± 7.51 |
| 8 Hour Post-dose | -4.5 ± 5.64 | -6.2 ± 7.41 | 4.2 ± 8.00 | -3.4 ± 7.85 |
| 12 Hour Post-dose | 0.2 ± 6.32 | -0.8 ± 5.88 | 7.2 ± 8.94 | 0.1 ± 4.51 |
| 16 Hour Post-dose | 3.6 ± 8.14 | 3.8 ± 7.79 | 9.6 ± 6.99 | 3.7 ± 6.89 |
| 24 Hour Post-dose | -3.8 ± 8.18 | -4.1 ± 6.16 | 0.9 ± 6.97 | -4.9 ± 6.05 |
The effect of evobrutinib on baseline-corrected measurements of QTcP was summarized by treatment and time points using descriptive statistics. Absolute change from baseline values was reported.
| milliseconds | Evobrutinib 45mg | Evobrutinib 225mg | Moxifloxacin 400mg | Placebo |
|---|---|---|---|---|
| Baseline | 388.2 ± 17.69 | 387.5 ± 17.40 | 389.1 ± 17.18 | 388.9 ± 17.08 |
| 15 Minutes Post-dose | 1.9 ± 5.21 | 2.1 ± 5.54 | -0.1 ± 4.06 | 3.2 ± 3.71 |
| 30 Minutes Post-dose | 0.8 ± 5.51 | 0.1 ± 4.57 | 2.5 ± 6.65 | 1.9 ± 4.32 |
| 1 Hour Post-dose | -0.6 ± 4.91 | -0.3 ± 5.15 | 9.8 ± 7.30 | 2.5 ± 5.47 |
| 1.5 Hour Post-dose | -3.1 ± 4.95 | -3.4 ± 5.18 | 10.9 ± 8.35 | 1.7 ± 5.45 |
| 2 Hour Post-dose | -2.4 ± 4.06 | -3.1 ± 3.94 | 13.0 ± 8.26 | -0.1 ± 5.33 |
| 2.5 Hour Post-dose | -3.1 ± 5.59 | -3.7 ± 5.20 | 10.7 ± 6.57 | -1.3 ± 4.45 |
| 3 Hour Post-dose | -3.7 ± 6.33 | -3.5 ± 4.60 | 11.7 ± 5.43 | -1.2 ± 5.18 |
| 4 Hour Post-dose | -2.9 ± 5.43 | -2.0 ± 5.71 | 9.4 ± 6.86 | -1.0 ± 5.65 |
| 6 Hour Post-dose | -2.6 ± 7.96 | -1.7 ± 7.46 | 5.8 ± 8.54 | -0.0 ± 7.63 |
| 8 Hour Post-dose | -3.0 ± 6.12 | -5.2 ± 7.82 | 6.3 ± 8.36 | -1.4 ± 8.29 |
| 12 Hour Post-dose | 0.8 ± 6.20 | -0.9 ± 5.90 | 8.2 ± 9.62 | 0.3 ± 4.98 |
| 16 Hour Post-dose | 4.9 ± 8.65 | 4.5 ± 8.10 | 11.3 ± 7.53 | 5.8 ± 7.07 |
| 24 Hour Post-dose | -1.5 ± 8.22 | -3.2 ± 6.86 | 2.5 ± 7.33 | -2.9 ± 6.47 |
The effect of evobrutinib on baseline-corrected measurements of PR interval was summarized by treatment and time points using descriptive statistics. Absolute change from baseline values was reported.
| milliseconds | Evobrutinib 45mg | Evobrutinib 225mg | Moxifloxacin 400mg | Placebo |
|---|---|---|---|---|
| Baseline | 166.7 ± 16.59 | 170.4 ± 17.93 | 167.7 ± 17.73 | 167.1 ± 17.99 |
| 15 Minutes Post-dose | -0.2 ± 4.66 | -1.2 ± 5.29 | -0.8 ± 4.01 | -1.3 ± 4.36 |
| 30 Minutes Post-dose | 0.5 ± 3.72 | 2.6 ± 4.37 | -1.2 ± 5.27 | 0.1 ± 5.14 |
| 1 Hour Post-dose | 1.1 ± 4.13 | 1.2 ± 4.04 | -1.5 ± 7.52 | -0.8 ± 5.11 |
| 1.5 Hour Post-dose | 1.9 ± 5.11 | 0.9 ± 5.15 | -1.9 ± 7.41 | -0.9 ± 5.69 |
| 2 Hour Post-dose | 0.9 ± 4.91 | -0.5 ± 3.59 | -2.5 ± 8.15 | -0.3 ± 5.24 |
| 2.5 Hour Post-dose | 0.6 ± 4.64 | -1.8 ± 5.20 | -3.5 ± 6.49 | -1.4 ± 6.69 |
| 3 Hour Post-dose | 0.1 ± 5.69 | -1.5 ± 5.45 | -3.7 ± 7.42 | -3.0 ± 5.16 |
| 4 Hour Post-dose | -0.5 ± 7.11 | -1.2 ± 5.01 | -3.6 ± 7.77 | -4.2 ± 4.16 |
| 6 Hour Post-dose | -9.3 ± 7.52 | -9.4 ± 4.73 | -10.6 ± 8.22 | -11.1 ± 8.48 |
| 8 Hour Post-dose | -8.3 ± 6.98 | -9.3 ± 6.53 | -9.3 ± 7.30 | -11.1 ± 7.17 |
| 12 Hour Post-dose | -2.2 ± 7.43 | -3.9 ± 8.28 | -3.6 ± 8.03 | -2.8 ± 6.28 |
| 16 Hour Post-dose | -2.6 ± 8.70 | -5.2 ± 7.20 | -3.1 ± 7.95 | -4.1 ± 6.25 |
| 24 Hour Post-dose | -1.0 ± 7.00 | -2.6 ± 6.14 | -0.5 ± 9.38 | -1.2 ± 7.99 |
The effect of evobrutinib on baseline-corrected measurements of QRS duration was summarized by treatment and time points using descriptive statistics. Absolute change from baseline values was reported.
| milliseconds | Evobrutinib 45mg | Evobrutinib 225mg | Moxifloxacin 400mg | Placebo |
|---|---|---|---|---|
| Baseline | 91.7 ± 8.28 | 91.8 ± 8.24 | 91.7 ± 8.11 | 91.0 ± 8.12 |
| 15 Minutes Post-dose | 0.1 ± 1.44 | 0.3 ± 1.15 | 0.1 ± 1.31 | 0.4 ± 1.23 |
| 30 Minutes Post-dose | 0.4 ± 1.25 | 0.4 ± 1.41 | -0.4 ± 1.22 | 0.7 ± 1.44 |
| 1 Hour Post-dose | -0.1 ± 1.20 | 0.4 ± 1.02 | 0.2 ± 1.26 | 0.5 ± 1.29 |
| 1.5 Hour Post-dose | -0.4 ± 1.30 | -0.2 ± 1.29 | -0.1 ± 1.16 | -0.1 ± 1.15 |
| 2 Hour Post-dose | -0.5 ± 1.17 | -0.6 ± 1.47 | -0.1 ± 1.42 | -0.5 ± 1.60 |
| 2.5 Hour Post-dose | -0.6 ± 1.29 | -0.3 ± 1.64 | -0.2 ± 1.27 | -0.3 ± 1.59 |
| 3 Hour Post-dose | -0.5 ± 1.35 | -0.1 ± 1.50 | -0.1 ± 1.03 | -0.1 ± 1.35 |
| 4 Hour Post-dose | -0.7 ± 1.41 | -0.3 ± 1.71 | -0.4 ± 1.70 | 0.0 ± 1.53 |
| 6 Hour Post-dose | -0.6 ± 2.26 | -0.5 ± 2.12 | -0.6 ± 1.70 | -0.4 ± 1.98 |
| 8 Hour Post-dose | -0.8 ± 1.99 | -0.5 ± 1.78 | -0.1 ± 1.82 | 0.4 ± 1.97 |
| 12 Hour Post-dose | -0.2 ± 1.95 | 0.2 ± 2.14 | 0.2 ± 1.45 | 0.2 ± 1.85 |
| 16 Hour Post-dose | 0.0 ± 1.91 | 0.4 ± 1.74 | 0.6 ± 1.90 | 0.8 ± 2.08 |
| 24 Hour Post-dose | 0.5 ± 1.93 | 0.1 ± 1.22 | 0.3 ± 1.31 | 0.5 ± 1.43 |
Collected over Up to 3 months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/32 (0%) | 0/32 (0%) | 8/32 (25%) |
| 400 mg Moxifloxacin | 0/32 (0%) | 0/32 (0%) | 5/32 (15.6%) |
| 45 mg Evobrutinib | 0/31 (0%) | 0/31 (0%) | 8/31 (25.8%) |
| 225 mg Evobrutinib | 0/32 (0%) | 0/32 (0%) | 5/32 (15.6%) |
| Event | Placebo | 400 mg Moxifloxacin | 45 mg Evobrutinib | 225 mg Evobrutinib |
|---|---|---|---|---|
| HeadacheNervous system disorders | 4/32 | 3/32 | 1/31 | 0/32 |
| Atrioventricular block second degreeCardiac disorders | 1/32 | 0/32 | 1/31 | 0/32 |
| Ventricular tachycardiaCardiac disorders | 0/32 | 0/32 | 1/31 | 1/32 |
| ConjunctivitisInfections and infestations | 0/32 | 0/32 | 1/31 | 0/32 |
| NasopharyngitisInfections and infestations | 0/32 | 0/32 | 1/31 | 0/32 |
| Back painMusculoskeletal and connective tissue disorders | 0/32 | 0/32 | 1/31 | 1/32 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 0/32 | 0/32 | 1/31 | 0/32 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 0/32 | 0/32 | 1/31 | 0/32 |
| Ventricular extrasystolesCardiac disorders | 1/32 | 0/32 | 0/31 | 1/32 |
| DiarrhoeaGastrointestinal disorders | 1/32 | 0/32 | 0/31 | 0/32 |
The safety analysis set included all participants who were administered any dose of any study intervention.
| Age, Continuous(Years) | Sequence 1 | Sequence 2 | Sequence 3 | Sequence 4 | Total |
|---|---|---|---|---|---|
| Mean | 45 ± 7.5 | 36 ± 10.4 | 41 ± 8.6 | 40 ± 11.3 | 41 ± 9.6 |
| Sex: Female, Male(Participants) | Sequence 1 | Sequence 2 | Sequence 3 | Sequence 4 | Total |
|---|---|---|---|---|---|
| Female | 3 | 2 | 2 | 1 | 8 |
| Male | 6 | 7 | 7 | 7 | 27 |
| Ethnicity (NIH/OMB)(Participants) | Sequence 1 | Sequence 2 | Sequence 3 | Sequence 4 | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 9 | 9 | 9 | 8 | 35 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Sequence 1 | Sequence 2 | Sequence 3 | Sequence 4 | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 1 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 1 | 0 | 0 | 2 |
| White | 8 | 8 | 8 | 8 | 32 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — We are committed to enhancing public health through responsible sharing of clinical trial data. Following approval of a new product or a new indication for an approved product in both the US and the European Union, the study sponsor and/or its affiliated companies will share study protocols, anonymized patient data and study level data, and redacted clinical study reports with qualified scientific and medical researchers, upon request, as necessary for conducting legitimate research. Further information on how to request data can be found on our website bit.ly/IPD21
Ran from Nov 2022 to primary completion in Aug 2023, 9 months.
Results were first posted in Nov 2025, 2 years 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Evobrutinib
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany →